Diffuse Large B-Cell Lymphoma Pipeline: 70+ Trailblazing Companies Driving the Next Wave of Precision Therapies | DelveInsight

The Diffuse Large B-Cell Lymphoma (DLBCL) market is on the brink of a transformative shift, fueled by the innovation of over 70 companies. More than 20 prominent biotech and pharmaceutical players-including Ranok Therapeutics, Monte Rosa Therapeutics, Otsuka Pharmaceutical, and OncoNano Medicine-are leading the charge with cutting-edge therapies aimed at delivering enhanced precision, improved efficacy, and better patient outcomes.

DelveInsight's "Diffuse Large B-Cell Lymphoma Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the diffuse large B-cell lymphoma market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging DLBCL drugs, the DLBCL pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Diffuse Large B-Cell Lymphoma Pipeline Report
• DelveInsight's diffuse large B-cell lymphoma pipeline analysis depicts a robust space with 70+ active players working to develop 75+ pipeline drugs for diffuse large B-cell lymphoma treatment.
• The leading DLBCL companies include Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology, and others are evaluating their lead assets to improve the DLBCL treatment landscape.
• Key DLBCL pipeline therapies in various stages of development include MB-CART2019.1, ADI-001, Zilovertamab vedotin, VAY736, THOR-707, Tazemetostat, SGR-1505, SC291, RNK05047, MRT-2359, OPB-111077, ONM-501, Odronextamab, Obinutuzumab, CC-122, NX-5948, and others.
• In March 2025, the FDA granted Fast Track Designation to azercabtagene zapreleucel (azer-cel), a CAR T-cell therapy by Imugene, for treating relapsed or refractory DLBCL, as announced in the company's press release.
• In February 2025, Pfizer Inc. announced the FDA's approval of ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and a rituximab product for treating adult patients with certain types of relapsed or refractory large B-cell lymphoma (LBCL).
• In January 2025, Roche announced that it received 510(k) clearance from the U.S. FDA for its VENTANA® Kappa and Lambda Dual ISH mRNA Probe Cocktail, a highly-sensitive in-situ hybridization (ISH) test. The test aids pathologists in distinguishing B-cell malignancies from normal reactive responses to infections, enabling quicker treatment decisions. This follows the assay's CE Mark approval in June 2024.
• In December 2024, ADC Therapeutics completed enrollment for LOTIS-5, its Phase 3 trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) with rituximab in relapsed/refractory DLBCL. ZYNLONTA received accelerated FDA approval in 2021 for r/r DLBCL after two or more prior therapies.
• In September 2023, AbbVie announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory R/R DLBCL after two or more lines of systemic therapy. TEPKINLY is the first and only subcutaneous T-cell engaging bispecific antibody approved for the treatment of this patient population in the European Union (EU).

Request a sample and discover the recent breakthroughs happening in the DLBCL pipeline landscape @ https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Diffuse Large B-Cell Lymphoma Overview
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma, representing 25-30% of cases. It usually presents as rapidly growing nodal or extranodal masses and may be associated with B symptoms like fever, night sweats, and weight loss in about 30% of patients. Bone marrow and extranodal involvement are common (seen in up to 50% of cases), with symptoms sometimes resulting from local compression (e.g., airway obstruction or SVC syndrome).

DLBCL arises from malignant B cells-often of germinal center origin-and is molecularly heterogeneous. Key genetic drivers include alterations in BCL2, BCL6, and MYC. Risk factors include immunodeficiency and infections like Epstein-Barr virus.

Diagnosis requires a combination of clinical assessment, lab work (CBC, LDH, HIV/hepatitis tests), imaging (PET/CT), and excisional biopsy for histology, immunophenotyping, and genetic profiling.

Treatment typically involves the R-CHOP regimen. High-risk or refractory cases may need intensified protocols or newer agents like lenalidomide or bortezomib. Early diagnosis and multidisciplinary care are key to improving outcomes, as DLBCL-despite its aggressiveness-can be curable with appropriate therapy.

Find out more about DLBCL medication @ https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Diffuse Large B-Cell Lymphoma Treatment Analysis: Drug Profile
THOR-707: Sanofi
THOR-707 is a PEGylated IL-2 variant designed to selectively stimulate tumor-fighting T effector and NK cells while avoiding toxicities linked to IL-2Rα binding. This precision-engineered cytokine aims to enhance anti-tumor immunity without inducing immunosuppression or vascular leak syndrome. It is currently in Phase II trials for DLBCL.

Abexinostat: Xynomic Pharmaceuticals
Abexinostat is a broad-spectrum histone deacetylase (HDAC) inhibitor that modifies histone and non-histone protein acetylation, leading to chromatin remodeling and altered gene expression. It is currently in Phase II clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL).

Key Diffuse Large B-Cell Lymphoma Therapies and Companies
• THOR-707: Sanofi
• Abexinostat: Xynomic Pharmaceuticals
• RNK05047: Ranok Therapeutics
• BMF-219: Biomea Fusion
• ADI-001: Adicet Bio
• Odronextamab: Regeneron Pharmaceuticals
• CALQUENCE (acalabrutinb): AstraZeneca
• Enzastaurin (DB102): Denovo Biopharma

Learn more about the novel and emerging DLBCL pipeline therapies @ https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Diffuse Large B-Cell Lymphoma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Diffuse Large B-Cell Lymphoma Pipeline Report
• Coverage: Global
• Key Diffuse Large B-Cell Lymphoma Companies: Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology, and others.
• Key Diffuse Large B-Cell Lymphoma Pipeline Therapies: MB-CART2019.1, ADI-001, Zilovertamab vedotin, VAY736, THOR-707, Tazemetostat, SGR-1505, SC291, RNK05047, MRT-2359, OPB-111077, ONM-501, Odronextamab, Obinutuzumab, CC-122, NX-5948, and others.

Dive deep into rich insights for drugs used for DLBCL treatment; visit @ https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Diffuse Large B-Cell Lymphoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Diffuse Large B-Cell Lymphoma Pipeline Therapeutics
6. Diffuse Large B-Cell Lymphoma Pipeline: Late-Stage Products (Phase III)
7. Diffuse Large B-Cell Lymphoma Pipeline: Mid-Stage Products (Phase II)
8. Diffuse Large B-Cell Lymphoma Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.